Literature DB >> 3134615

Neurofibromatosis 2: clinical and DNA linkage studies of a large kindred.

W Wertelecki1, G A Rouleau, D W Superneau, L W Forehand, J P Williams, J L Haines, J F Gusella.   

Abstract

At least eight provisional categories of neurofibromatosis have been proposed. Among these, neurofibromatosis 1 (von Recklinghausen's disease or peripheral neurofibromatosis) and neurofibromatosis 2 (central or bilateral acoustic neurofibromatosis) have been established as distinct disorders. We studied 15 affected male and 8 affected female members of one large kindred with neurofibromatosis 2. None of the patients met the diagnostic criteria for neurofibromatosis 1. Between the ages of 15 and 53 years, the patients had multiple central nervous system tumors of various types--mainly, bilateral acoustic neuromas. Two or more tumors eventually developed in 20 of the patients; 9 had evidence of only bilateral acoustic neuromas. Meningiomas and ependymomas were more common among the young patients; those who initially presented with acoustic neuromas were nearly a decade older. Intracranial nontumoral calcifications were present in most patients and were also found in symptom-free children. The presence of such lesions is probably a prodromic feature of neurofibromatosis 2. Simultaneous analysis of D22S1 and IGLV DNA markers for coinheritance with neurofibromatosis 2 indicates that the locus for the disease is near the center of the long arm of chromosome 22 (22q11.1----22q13.1). The eventual isolation of this disease gene may reveal a cause of the most common intracranial tumors in humans.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3134615     DOI: 10.1056/NEJM198808043190505

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  19 in total

1.  Flanking markers bracket the neurofibromatosis type 2 (NF2) gene on chromosome 22.

Authors:  G A Rouleau; B R Seizinger; W Wertelecki; J L Haines; D W Superneau; R L Martuza; J F Gusella
Journal:  Am J Hum Genet       Date:  1990-02       Impact factor: 11.025

Review 2.  Recent developments in the diagnosis and management of neurofibromatosis.

Authors:  S M Huson
Journal:  Arch Dis Child       Date:  1989-05       Impact factor: 3.791

3.  Chromosomes 17 and 22 involved in marker formation in neurofibrosarcoma in von Recklinghausen disease. A cytogenetic and in situ hybridization study.

Authors:  H J Decker; L A Cannizzaro; M J Mendez; S P Leong; H Bixenman; C Berger; A A Sandberg
Journal:  Hum Genet       Date:  1990-08       Impact factor: 4.132

Review 4.  Clinical and genetic patterns of neurofibromatosis 1 and 2.

Authors:  N K Ragge
Journal:  Br J Ophthalmol       Date:  1993-10       Impact factor: 4.638

5.  A t(4;22) in a meningioma points to the localization of a putative tumor-suppressor gene.

Authors:  R H Lekanne Deprez; N A Groen; N A van Biezen; A Hagemeijer; E van Drunen; J W Koper; C J Avezaat; D Bootsma; E C Zwarthoff
Journal:  Am J Hum Genet       Date:  1991-04       Impact factor: 11.025

6.  Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease.

Authors:  M H Ruttledge; A A Andermann; C M Phelan; J O Claudio; F Y Han; N Chretien; S Rangaratnam; M MacCollin; P Short; D Parry; V Michels; V M Riccardi; R Weksberg; K Kitamura; J M Bradburn; B D Hall; P Propping; G A Rouleau
Journal:  Am J Hum Genet       Date:  1996-08       Impact factor: 11.025

7.  Radiological investigation of neurofibromatosis type 2.

Authors:  P Akeson; S Holtås
Journal:  Neuroradiology       Date:  1994       Impact factor: 2.804

Review 8.  Pathology of meningiomas.

Authors:  L A Langford
Journal:  J Neurooncol       Date:  1996-09       Impact factor: 4.130

9.  A prospective study of cavernous sinus surgery for meningiomas and resultant common ophthalmic complications (an American Ophthalmological Society thesis).

Authors:  Steven Newman
Journal:  Trans Am Ophthalmol Soc       Date:  2007

Review 10.  Meningiomas of the cranial base.

Authors:  R Desai; J Bruce
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.